Aytu BioPharma (NASDAQ: AYTU) reported a Q loss of $0.82/share ($0.37 miss), $17.98M revenue, -14.

Aytu BioPharma (NASDAQ: AYTU) reported a quarterly loss of $0.82 per share, missing estimates by $0.37. The company earned $17.98 million in revenue, with a negative net margin of 14.60% and a return on equity of -31.31%. Following the report, shares fell to $2.36, and the market cap stands at $14.09 million. Aytu BioPharma specializes in novel therapeutics and consumer healthcare products, including treatments for ADHD.

September 28, 2024
6 Articles

Further Reading